Manuel David Gil-Sierra, Theo Mantopoulos, Ifigeneia Barouma, Ole Hauch, Zhaoyang Teng, Cedric Fernandez, Sean Corbet, Max Schlueter
{"title":"伊沃西地尼与其他治疗方法对新诊断急性髓系白血病的间接治疗比较。","authors":"Manuel David Gil-Sierra, Theo Mantopoulos, Ifigeneia Barouma, Ole Hauch, Zhaoyang Teng, Cedric Fernandez, Sean Corbet, Max Schlueter","doi":"10.1080/14796694.2025.2515778","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To assess the relative efficacy of ivosidenib + azacitidine versus other therapies (venetoclax, glasdegib, azacitidine, decitabine and low-dose cytarabine [LDAC]) for the treatment of patients with newly diagnosed IDH1-mutated (mIDH1) acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy.</p><p><strong>Methods: </strong>A systematic literature review (SLR) was conducted to identify evidence from studies assessing the clinical efficacy of therapies in the population of interest. The relative efficacy of ivosidenib + azacitidine was estimated using a network meta-analysis (NMA) for overall survival (OS) and event-free survival (EFS). In addition, an anchored matching-adjusted indirect comparison (MAIC) of OS was conducted against venetoclax + azacitidine to account for population imbalances.</p><p><strong>Results: </strong>Following the SLR and feasibility assessment, six studies were considered eligible for inclusion in the NMA. The NMA included all population types identified in the relevant studies (including patients with and without mIDH1) and determined ivosidenib + azacitidine as the treatment with the greatest effect. The MAIC showed that ivosidenib + azacitidine was associated with numerically favorable OS compared to venetoclax + azacitidine.</p><p><strong>Conclusion: </strong>Both NMA and MAIC methods generated consistent results, demonstrating a benefit of ivosidenib + azacitidine versus other therapies for the treatment of newly diagnosed IDH1m AML.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Indirect treatment comparison of ivosidenib and other therapies in patients with newly diagnosed acute myeloid leukemia.\",\"authors\":\"Manuel David Gil-Sierra, Theo Mantopoulos, Ifigeneia Barouma, Ole Hauch, Zhaoyang Teng, Cedric Fernandez, Sean Corbet, Max Schlueter\",\"doi\":\"10.1080/14796694.2025.2515778\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To assess the relative efficacy of ivosidenib + azacitidine versus other therapies (venetoclax, glasdegib, azacitidine, decitabine and low-dose cytarabine [LDAC]) for the treatment of patients with newly diagnosed IDH1-mutated (mIDH1) acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy.</p><p><strong>Methods: </strong>A systematic literature review (SLR) was conducted to identify evidence from studies assessing the clinical efficacy of therapies in the population of interest. The relative efficacy of ivosidenib + azacitidine was estimated using a network meta-analysis (NMA) for overall survival (OS) and event-free survival (EFS). In addition, an anchored matching-adjusted indirect comparison (MAIC) of OS was conducted against venetoclax + azacitidine to account for population imbalances.</p><p><strong>Results: </strong>Following the SLR and feasibility assessment, six studies were considered eligible for inclusion in the NMA. The NMA included all population types identified in the relevant studies (including patients with and without mIDH1) and determined ivosidenib + azacitidine as the treatment with the greatest effect. The MAIC showed that ivosidenib + azacitidine was associated with numerically favorable OS compared to venetoclax + azacitidine.</p><p><strong>Conclusion: </strong>Both NMA and MAIC methods generated consistent results, demonstrating a benefit of ivosidenib + azacitidine versus other therapies for the treatment of newly diagnosed IDH1m AML.</p>\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"1-11\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2025.2515778\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2515778","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Indirect treatment comparison of ivosidenib and other therapies in patients with newly diagnosed acute myeloid leukemia.
Aim: To assess the relative efficacy of ivosidenib + azacitidine versus other therapies (venetoclax, glasdegib, azacitidine, decitabine and low-dose cytarabine [LDAC]) for the treatment of patients with newly diagnosed IDH1-mutated (mIDH1) acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy.
Methods: A systematic literature review (SLR) was conducted to identify evidence from studies assessing the clinical efficacy of therapies in the population of interest. The relative efficacy of ivosidenib + azacitidine was estimated using a network meta-analysis (NMA) for overall survival (OS) and event-free survival (EFS). In addition, an anchored matching-adjusted indirect comparison (MAIC) of OS was conducted against venetoclax + azacitidine to account for population imbalances.
Results: Following the SLR and feasibility assessment, six studies were considered eligible for inclusion in the NMA. The NMA included all population types identified in the relevant studies (including patients with and without mIDH1) and determined ivosidenib + azacitidine as the treatment with the greatest effect. The MAIC showed that ivosidenib + azacitidine was associated with numerically favorable OS compared to venetoclax + azacitidine.
Conclusion: Both NMA and MAIC methods generated consistent results, demonstrating a benefit of ivosidenib + azacitidine versus other therapies for the treatment of newly diagnosed IDH1m AML.
期刊介绍：
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
